H2N2 live attenuated influenza vaccine is safe and immunogenic for healthy adult volunteers
Identifieur interne : 000B54 ( Ncbi/Curation ); précédent : 000B53; suivant : 000B55H2N2 live attenuated influenza vaccine is safe and immunogenic for healthy adult volunteers
Auteurs : Irina Isakova-Sivak [Russie] ; Marina Stukova [Russie] ; Mariana Erofeeva [Russie] ; Anatoly Naykhin [Russie] ; Svetlana Donina [Russie] ; Galina Petukhova [Russie] ; Victoria Kuznetsova [Russie] ; Irina Kiseleva [Russie] ; Tatiana Smolonogina [Russie] ; Irina Dubrovina [Russie] ; Maria Pisareva [Russie] ; Alexandra Nikiforova [Russie] ; Maureen Power [États-Unis] ; Jorge Flores [États-Unis] ; Larisa Rudenko [Russie]Source :
- Human Vaccines & Immunotherapeutics [ 2164-5515 ] ; 2015.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Femelle, Grippe humaine (), Humains, Jeune adulte, Mâle, Méthode en double aveugle, Sous-type H2N2 du virus de la grippe A (immunologie), Vaccins antigrippaux (effets indésirables), Vaccins antigrippaux (immunologie), Vaccins antigrippaux (usage thérapeutique), Volontaires sains.
- MESH :
- effets indésirables : Vaccins antigrippaux.
- immunologie : Sous-type H2N2 du virus de la grippe A, Vaccins antigrippaux.
- usage thérapeutique : Vaccins antigrippaux.
- Adolescent, Adulte, Femelle, Grippe humaine, Humains, Jeune adulte, Mâle, Méthode en double aveugle, Volontaires sains.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Influenza Vaccines.
- immunology : Influenza A Virus, H2N2 Subtype, Influenza Vaccines.
- prevention & control : Influenza, Human.
- chemical , therapeutic use : Influenza Vaccines.
- Adolescent, Adult, Double-Blind Method, Female, Healthy Volunteers, Humans, Male, Young Adult.
Abstract
H2N2 influenza viruses have not circulated in the human population since 1968, but they are still being regularly detected in the animal reservoir, suggesting their high pandemic potential. To prepare for a possible H2N2 pandemic, a number of H2N2 vaccine candidates have been generated and tested in preclinical and clinical studies. Here we describe the results of a randomized, double-blind placebo-controlled phase 1 clinical trial of an H2N2 live attenuated influenza vaccine (LAIV) candidate prepared from a human influenza virus isolated in 1966. The vaccine candidate was safe and well-tolerated by healthy adults, and did not cause serious adverse events or an increased rate of moderate or severe reactogenicities. The H2N2 vaccine virus was infectious for Humans. It was shed by 78.6% and 74.1% volunteers after the first and second dose, respectively, most probably due to the human origin of the virus. Importantly, no vaccine virus transmission to unvaccinated subjects was detected during the study. We employed multiple immunological tests to ensure the adequate assessment of the H2N2 pandemic LAIV candidate and demonstrated that the majority (92.6%) of the vaccinated subjects responded to the H2N2 LAIV in one or more immunological tests, including 85.2% of subjects with antibody responses and 55.6% volunteers with cell-mediated immune responses. In addition, we observed strong correlation between the H2N2 LAIV virus replication in the upper respiratory tract and the development of antibody responses.
Url:
DOI: 10.1080/21645515.2015.1010859
PubMed: 25831405
PubMed Central: 4514355
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000017
- to stream Pmc, to step Curation: Pour aller vers cette notice dans l'étape Curation :000017
- to stream Pmc, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000397
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000079
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000079
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000071
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000B54
Links to Exploration step
PMC:4514355Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">H2N2 live attenuated influenza vaccine is safe and immunogenic for healthy adult volunteers</title>
<author><name sortKey="Isakova Sivak, Irina" sort="Isakova Sivak, Irina" uniqKey="Isakova Sivak I" first="Irina" last="Isakova-Sivak">Irina Isakova-Sivak</name>
<affiliation wicri:level="1"><nlm:aff id="af0001"><institution>Institute of Experimental Medicine RAMS</institution>
; Saint Petersburg,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Stukova, Marina" sort="Stukova, Marina" uniqKey="Stukova M" first="Marina" last="Stukova">Marina Stukova</name>
<affiliation wicri:level="1"><nlm:aff id="af0002"><institution>Research Institute of Influenza;</institution>
Saint Petersburg,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Erofeeva, Mariana" sort="Erofeeva, Mariana" uniqKey="Erofeeva M" first="Mariana" last="Erofeeva">Mariana Erofeeva</name>
<affiliation wicri:level="1"><nlm:aff id="af0002"><institution>Research Institute of Influenza;</institution>
Saint Petersburg,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Naykhin, Anatoly" sort="Naykhin, Anatoly" uniqKey="Naykhin A" first="Anatoly" last="Naykhin">Anatoly Naykhin</name>
<affiliation wicri:level="1"><nlm:aff id="af0001"><institution>Institute of Experimental Medicine RAMS</institution>
; Saint Petersburg,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Donina, Svetlana" sort="Donina, Svetlana" uniqKey="Donina S" first="Svetlana" last="Donina">Svetlana Donina</name>
<affiliation wicri:level="1"><nlm:aff id="af0001"><institution>Institute of Experimental Medicine RAMS</institution>
; Saint Petersburg,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Petukhova, Galina" sort="Petukhova, Galina" uniqKey="Petukhova G" first="Galina" last="Petukhova">Galina Petukhova</name>
<affiliation wicri:level="1"><nlm:aff id="af0001"><institution>Institute of Experimental Medicine RAMS</institution>
; Saint Petersburg,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kuznetsova, Victoria" sort="Kuznetsova, Victoria" uniqKey="Kuznetsova V" first="Victoria" last="Kuznetsova">Victoria Kuznetsova</name>
<affiliation wicri:level="1"><nlm:aff id="af0001"><institution>Institute of Experimental Medicine RAMS</institution>
; Saint Petersburg,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kiseleva, Irina" sort="Kiseleva, Irina" uniqKey="Kiseleva I" first="Irina" last="Kiseleva">Irina Kiseleva</name>
<affiliation wicri:level="1"><nlm:aff id="af0001"><institution>Institute of Experimental Medicine RAMS</institution>
; Saint Petersburg,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Smolonogina, Tatiana" sort="Smolonogina, Tatiana" uniqKey="Smolonogina T" first="Tatiana" last="Smolonogina">Tatiana Smolonogina</name>
<affiliation wicri:level="1"><nlm:aff id="af0001"><institution>Institute of Experimental Medicine RAMS</institution>
; Saint Petersburg,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Dubrovina, Irina" sort="Dubrovina, Irina" uniqKey="Dubrovina I" first="Irina" last="Dubrovina">Irina Dubrovina</name>
<affiliation wicri:level="1"><nlm:aff id="af0001"><institution>Institute of Experimental Medicine RAMS</institution>
; Saint Petersburg,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Pisareva, Maria" sort="Pisareva, Maria" uniqKey="Pisareva M" first="Maria" last="Pisareva">Maria Pisareva</name>
<affiliation wicri:level="1"><nlm:aff id="af0002"><institution>Research Institute of Influenza;</institution>
Saint Petersburg,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nikiforova, Alexandra" sort="Nikiforova, Alexandra" uniqKey="Nikiforova A" first="Alexandra" last="Nikiforova">Alexandra Nikiforova</name>
<affiliation wicri:level="1"><nlm:aff id="af0003"><institution>Department of Preclinical Trials; Microgen</institution>
, Moscow,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Power, Maureen" sort="Power, Maureen" uniqKey="Power M" first="Maureen" last="Power">Maureen Power</name>
<affiliation wicri:level="1"><nlm:aff id="af0004"><institution>PATH;</institution>
Seattle, WA<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Flores, Jorge" sort="Flores, Jorge" uniqKey="Flores J" first="Jorge" last="Flores">Jorge Flores</name>
<affiliation wicri:level="1"><nlm:aff id="af0004"><institution>PATH;</institution>
Seattle, WA<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rudenko, Larisa" sort="Rudenko, Larisa" uniqKey="Rudenko L" first="Larisa" last="Rudenko">Larisa Rudenko</name>
<affiliation wicri:level="1"><nlm:aff id="af0001"><institution>Institute of Experimental Medicine RAMS</institution>
; Saint Petersburg,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">25831405</idno>
<idno type="pmc">4514355</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514355</idno>
<idno type="RBID">PMC:4514355</idno>
<idno type="doi">10.1080/21645515.2015.1010859</idno>
<date when="2015">2015</date>
<idno type="wicri:Area/Pmc/Corpus">000017</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000017</idno>
<idno type="wicri:Area/Pmc/Curation">000017</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000017</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000397</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000397</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:25831405</idno>
<idno type="wicri:Area/PubMed/Corpus">000079</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000079</idno>
<idno type="wicri:Area/PubMed/Curation">000079</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000079</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000071</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000071</idno>
<idno type="wicri:Area/Ncbi/Merge">000B54</idno>
<idno type="wicri:Area/Ncbi/Curation">000B54</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">H2N2 live attenuated influenza vaccine is safe and immunogenic for healthy adult volunteers</title>
<author><name sortKey="Isakova Sivak, Irina" sort="Isakova Sivak, Irina" uniqKey="Isakova Sivak I" first="Irina" last="Isakova-Sivak">Irina Isakova-Sivak</name>
<affiliation wicri:level="1"><nlm:aff id="af0001"><institution>Institute of Experimental Medicine RAMS</institution>
; Saint Petersburg,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Stukova, Marina" sort="Stukova, Marina" uniqKey="Stukova M" first="Marina" last="Stukova">Marina Stukova</name>
<affiliation wicri:level="1"><nlm:aff id="af0002"><institution>Research Institute of Influenza;</institution>
Saint Petersburg,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Erofeeva, Mariana" sort="Erofeeva, Mariana" uniqKey="Erofeeva M" first="Mariana" last="Erofeeva">Mariana Erofeeva</name>
<affiliation wicri:level="1"><nlm:aff id="af0002"><institution>Research Institute of Influenza;</institution>
Saint Petersburg,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Naykhin, Anatoly" sort="Naykhin, Anatoly" uniqKey="Naykhin A" first="Anatoly" last="Naykhin">Anatoly Naykhin</name>
<affiliation wicri:level="1"><nlm:aff id="af0001"><institution>Institute of Experimental Medicine RAMS</institution>
; Saint Petersburg,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Donina, Svetlana" sort="Donina, Svetlana" uniqKey="Donina S" first="Svetlana" last="Donina">Svetlana Donina</name>
<affiliation wicri:level="1"><nlm:aff id="af0001"><institution>Institute of Experimental Medicine RAMS</institution>
; Saint Petersburg,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Petukhova, Galina" sort="Petukhova, Galina" uniqKey="Petukhova G" first="Galina" last="Petukhova">Galina Petukhova</name>
<affiliation wicri:level="1"><nlm:aff id="af0001"><institution>Institute of Experimental Medicine RAMS</institution>
; Saint Petersburg,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kuznetsova, Victoria" sort="Kuznetsova, Victoria" uniqKey="Kuznetsova V" first="Victoria" last="Kuznetsova">Victoria Kuznetsova</name>
<affiliation wicri:level="1"><nlm:aff id="af0001"><institution>Institute of Experimental Medicine RAMS</institution>
; Saint Petersburg,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kiseleva, Irina" sort="Kiseleva, Irina" uniqKey="Kiseleva I" first="Irina" last="Kiseleva">Irina Kiseleva</name>
<affiliation wicri:level="1"><nlm:aff id="af0001"><institution>Institute of Experimental Medicine RAMS</institution>
; Saint Petersburg,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Smolonogina, Tatiana" sort="Smolonogina, Tatiana" uniqKey="Smolonogina T" first="Tatiana" last="Smolonogina">Tatiana Smolonogina</name>
<affiliation wicri:level="1"><nlm:aff id="af0001"><institution>Institute of Experimental Medicine RAMS</institution>
; Saint Petersburg,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Dubrovina, Irina" sort="Dubrovina, Irina" uniqKey="Dubrovina I" first="Irina" last="Dubrovina">Irina Dubrovina</name>
<affiliation wicri:level="1"><nlm:aff id="af0001"><institution>Institute of Experimental Medicine RAMS</institution>
; Saint Petersburg,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Pisareva, Maria" sort="Pisareva, Maria" uniqKey="Pisareva M" first="Maria" last="Pisareva">Maria Pisareva</name>
<affiliation wicri:level="1"><nlm:aff id="af0002"><institution>Research Institute of Influenza;</institution>
Saint Petersburg,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nikiforova, Alexandra" sort="Nikiforova, Alexandra" uniqKey="Nikiforova A" first="Alexandra" last="Nikiforova">Alexandra Nikiforova</name>
<affiliation wicri:level="1"><nlm:aff id="af0003"><institution>Department of Preclinical Trials; Microgen</institution>
, Moscow,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Power, Maureen" sort="Power, Maureen" uniqKey="Power M" first="Maureen" last="Power">Maureen Power</name>
<affiliation wicri:level="1"><nlm:aff id="af0004"><institution>PATH;</institution>
Seattle, WA<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Flores, Jorge" sort="Flores, Jorge" uniqKey="Flores J" first="Jorge" last="Flores">Jorge Flores</name>
<affiliation wicri:level="1"><nlm:aff id="af0004"><institution>PATH;</institution>
Seattle, WA<country>USA</country>
</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rudenko, Larisa" sort="Rudenko, Larisa" uniqKey="Rudenko L" first="Larisa" last="Rudenko">Larisa Rudenko</name>
<affiliation wicri:level="1"><nlm:aff id="af0001"><institution>Institute of Experimental Medicine RAMS</institution>
; Saint Petersburg,<country>Russia</country>
</nlm:aff>
<country xml:lang="fr">Russie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Human Vaccines & Immunotherapeutics</title>
<idno type="ISSN">2164-5515</idno>
<idno type="eISSN">2164-554X</idno>
<imprint><date when="2015">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Healthy Volunteers</term>
<term>Humans</term>
<term>Influenza A Virus, H2N2 Subtype (immunology)</term>
<term>Influenza Vaccines (adverse effects)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza Vaccines (therapeutic use)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Male</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Femelle</term>
<term>Grippe humaine ()</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Méthode en double aveugle</term>
<term>Sous-type H2N2 du virus de la grippe A (immunologie)</term>
<term>Vaccins antigrippaux (effets indésirables)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Vaccins antigrippaux (usage thérapeutique)</term>
<term>Volontaires sains</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H2N2 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term>
<term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Influenza Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Vaccins antigrippaux</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Healthy Volunteers</term>
<term>Humans</term>
<term>Male</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Femelle</term>
<term>Grippe humaine</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Méthode en double aveugle</term>
<term>Volontaires sains</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>H2N2 influenza viruses have not circulated in the human population since 1968, but they are still being regularly detected in the animal reservoir, suggesting their high pandemic potential. To prepare for a possible H2N2 pandemic, a number of H2N2 vaccine candidates have been generated and tested in preclinical and clinical studies. Here we describe the results of a randomized, double-blind placebo-controlled phase 1 clinical trial of an H2N2 live attenuated influenza vaccine (LAIV) candidate prepared from a human influenza virus isolated in 1966. The vaccine candidate was safe and well-tolerated by healthy adults, and did not cause serious adverse events or an increased rate of moderate or severe reactogenicities. The H2N2 vaccine virus was infectious for Humans. It was shed by 78.6% and 74.1% volunteers after the first and second dose, respectively, most probably due to the human origin of the virus. Importantly, no vaccine virus transmission to unvaccinated subjects was detected during the study. We employed multiple immunological tests to ensure the adequate assessment of the H2N2 pandemic LAIV candidate and demonstrated that the majority (92.6%) of the vaccinated subjects responded to the H2N2 LAIV in one or more immunological tests, including 85.2% of subjects with antibody responses and 55.6% volunteers with cell-mediated immune responses. In addition, we observed strong correlation between the H2N2 LAIV virus replication in the upper respiratory tract and the development of antibody responses.</p>
</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B54 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000B54 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= H2N2V1 |flux= Ncbi |étape= Curation |type= RBID |clé= PMC:4514355 |texte= H2N2 live attenuated influenza vaccine is safe and immunogenic for healthy adult volunteers }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:25831405" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a H2N2V1
This area was generated with Dilib version V0.6.33. |